IN CASE YOU MISSED IT

PCLI Webinar: Implementation of Germline Testing for Prostate Cancer


The webinar was moderated by Edith P. Mitchell, MD, FACP, FCPP, director of the Center to Eliminate Cancer Disparities at Sidney Kimmel Cancer Center (SKCC) at Jefferson Health. Dr. Mitchell was joined by presenter Veda N. Giri, MD, director of Jefferson Clinical Cancer Genetics Service.

According to the American Cancer Society, prostate cancer is the number one cancer diagnosed in men in the United States, and the second leading cause of cancer-related death in U.S. males. Up to 17 percent of metastatic prostate cancer has a hereditary component, and higher risk has been seen in families with history of BRCA breast cancer, Lynch syndrome, and Ashkenazi Jewish ancestry.

SKCC's Philadelphia catchment area outpaces the state of Pennsylvania and the U.S. in prostate cancer risk and mortality. At last year's Philadelphia Prostate Cancer Consensus Conference, recommendations were developed for genetic counseling and testing, informed consent, and risk assessment. Dr. Giri shared an overview of these recommendations along with special considerations that have emerged in light of the COVID-19 pandemic, including virtual tumor boards and molecular boards and concerns surrounding reimbursement of telephone counseling and barriers to insurance coverage.